Literature DB >> 8203863

Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.

V Korten1, J F Tomayko, B E Murray.   

Abstract

The in vitro activity of DU-6859a (DU), a new fluoroquinolone agent, was evaluated against 233 gram-positive cocci and was compared with those of ciprofloxacin, vancomycin, nafcillin, and ampicillin. The MICs of DU for 90% of the staphylococci tested were < or = 0.06 microgram/ml. All of the groups A and B and viridans group streptococci were inhibited by < or = 0.125 microgram of DU per ml, which was 32-fold more active than ciprofloxacin. On the basis of MICs for 90% of the strains tested, DU was 32- and 16-fold more active than ciprofloxacin against Enterococcus faecalis and Enterococcus faecium, respectively. The bactericidal activity of DU was demonstrated by time-kill techniques against all ciprofloxacin-susceptible enterococci. DU shows promise for the treatment of infections with gram-positive cocci and warrants further evaluation by in vitro and in vivo studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203863      PMCID: PMC284507          DOI: 10.1128/AAC.38.3.611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.

Authors:  C W Stratton; C Liu; H B Ratner; L S Weeks
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.

Authors:  G M Eliopoulos; K Klimm; L B Rice; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites.

Authors:  B E Murray; K V Singh; J D Heath; B R Sharma; G M Weinstock
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

4.  WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  J Pharm Pharmacol       Date:  1991-07       Impact factor: 3.765

6.  In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Interaction of ciprofloxacin with ampicillin and vancomycin for Streptococcus faecalis.

Authors:  S M Smith; R H Eng
Journal:  Diagn Microbiol Infect Dis       Date:  1988-04       Impact factor: 2.803

8.  In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.

Authors:  D F Sahm; G T Koburov
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

10.  In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis.

Authors:  M Fernandez-Guerrero; M S Rouse; N K Henry; J E Geraci; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

View more
  8 in total

1.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

Authors:  E J Giamarellos-Bourboulis; H Sambatakou; P Grecka; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

Review 4.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

5.  Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 7.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 8.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.